卢非酰胺对癫痫的作用大吗？

It has a better effect on epilepsy. Rufinamide may reduce the frequency of epileptic seizures, possibly by increasing GABA (gamma-aminobutyric acid) neurotransmission and suppressing neural excitability. The use of this drug can help patients better control their epilepsy, reduce the number of seizures, and thus improve their quality of life.

About rufinamide

Rufinamide is mainly used to treat partial seizures and generalized tonic-clonic seizures in epilepsy. Partial seizures are a type of epileptic seizure that originate in a specific area of ​​the brain and may spread to other areas. Generalized tonic-clonic seizures are a common type of epilepsy in which patients experience sudden generalized tonic and clonic convulsions.

The mechanism of rufinamide is to control epileptic seizures by regulating the electrical activity of nerves. It limits the sodium ion channels inside the nerves, reduces the generation of abnormal excitatory potentials, thereby inhibiting the occurrence of epileptic seizures. In addition, it stabilizes cell membranes and reduces the spread of abnormal discharges.

Rufinamide usage and dosage

For adult patients with Lennox-Gastaut syndrome, the recommended starting daily dose of rufinamide is 400 to 800 mg per day, divided into two equal doses. After the initial dose, the dose may be increased by 400 to 800 mg every other day until the maximum daily dose of 3200 mg is reached, divided into two equal doses.

The following are some precautions to take when using rufinamide oral suspension:

1. Before each administration, the oral suspension should be shaken well to ensure that the drug is evenly dispersed.

2. Administer oral suspension using the adapter and calibrated oral dosage syringe provided. The adapter should be securely inserted into the bottle neck before use and remain in place during use.

3. Insert the dosing syringe into the adapter and draw the required dose from the inverted bottle.

4. The cover of the adapter should be replaced after each use to ensure hygiene.

The therapeutic effects of rufinamide

Rufinamide was launched in Europe in 2007 and was launched in the United States in 2008 based on a Phase II clinical trial. It is currently mainly used for the treatment of Lennox-Gastant syndrome in children over 1 year old, especially the treatment of tonic or atonic seizures.

In a phase III randomized double-blind placebo-controlled clinical trial involving 356 patients with refractory partial epilepsy, the seizure frequency of the rufinamide group was reduced by 23.25%, which was significantly lower than that of the placebo group (9.8%); the rate of epilepsy seizure reduction of ≥50% in the treatment group (32.5%) was significantly higher than that of the placebo group (14.3%). The adverse reactions caused by rufinamide are similar to those of other AEDs, but it should be noted that rufinamide can cause a shortening of the Q-T interval of the electrocardiogram.

The latest phase II clinical trial shows that reducing the initial dose of rufinamide and slowly increasing the dose can effectively reduce the incidence of adverse reactions without affecting the efficacy.

Summary

Rufinamide, as an anti-epileptic drug, plays an important role in the treatment of epilepsy. It regulates the electrical activity of nerves and suppresses abnormal excitatory potentials, thereby reducing the frequency and severity of epileptic seizures. Rufinamide is indicated for the treatment of partial-onset and generalized tonic-clonic seizures. Overall, rufinamide is an effective anti-epileptic drug that can help patients control epileptic seizures and improve their quality of life. However, for specific medication regimens and dosages, you should still consult a professional doctor for advice based on individual circumstances.

Recommended hot articles: